Clinical trial
CCI-779 in Treating Patients With Prostate Cancer
NCT00012142 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00012142 |
|---|---|
| Title | CCI-779 in Treating Patients With Prostate Cancer |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Phase II Study Of Intravenous CCI-779 Administered Weekly To Patients With Androgen-Independent Prostate Cancer |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | temsirolimus |
| Start date | Sep 1, 2000 |
| Completion | Mar 1, 2004 |
| First posted | Mar 26, 2004 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: